Solara Active Pharma Sciences Limited — Updates, 10-05-2025: Press Release

Solara has announced a board meeting to review the financial results for the quarter and half-year. Its Ambernath API manufacturing facility cleared the latest USFDA inspection with zero 483 observations for the third consecutive time, underscoring strong regulatory compliance and quality. This multi-product site maintains global standards, bolstering Solara’s position as a leading pure-play API manufacturer with extensive approvals and robust manufacturing capabilities.